News | Mobile Devices | June 13, 2018

Medisafe Demonstrates Double-Digit Impact on Hypertension Medication Adherence

Use of medication management mobile app increased prescription refill rates by almost 10 percent

Medisafe Demonstrates Double-Digit Impact on Hypertension Medication Adherence

June 13, 2018 — Medication management platform Medisafe released data showing that, on average, hypertensive patients increase their prescription refills by almost 10 percent after they start using the company's mobile app.

In order to determine the increase in prescription claims, the study matched Medisafe users to their refill data using a HIPAA-compliant, non-identification process. The investigators calculated a medication possession ratio ("MPR") for each of the over 4,000 patients taking an antihypertensive medication pre-app (before the patient started using Medisafe) and on-app (once the patient started using Medisafe) and grouped them into corresponding MPR deciles (0 - 0.1 being the least adherent, 0.9 - 1.0 being the most adherent). MPR is a standard metric used by the healthcare industry to track medication adherence, in which an MPR of 1.0 corresponds to a 100 percent refill rate.  

Key findings include:

  • Of patients not in the top MPR decile pre-app, 82 percent (1,371 of 1,667) increased by at least one decile on-app;
  • Of patients with a pre-app MPR < 0.8, 78 percent (920 of 1,179) increased by at least 2 deciles;
  • Of patients with a pre-app MPR < 0.5, 74 percent of patients (320 of 431) increased by at least 5 deciles; and
  • The proportion of patients with MPR ≥ 0.80 increased from 70.8 percent pre-app to 86.25 percent on-app, a 21.8 percent relative increase.

 

Summary Table

Adherence (MPR) Pre-app On-app p-value % change
Mean 0.84 0.92 <.0001 9.52%
Standard deviation 0.23 0.13    
Adherent [MPR ≥ 0.80] 2858 (71%) 3482 (86%) <.0001 21.13%

N= 4,037

 

The hypertension results follow data released from the same landmark study in early March on the accuracy of Medisafe's patient reported adherence data. In the coming months, Medisafe will continue to release results, including data regarding the platform's impact on adherence and persistence across other therapeutic areas.

For more information: www.medisafe.com


Related Content

News | Cardiovascular Clinical Studies

April 20, 2023 — Researchers led by Northwestern University and the University of Texas at Austin (UT) have developed ...

Home April 20, 2023
Home
News | Cardiovascular Clinical Studies

April 5, 2023 — Acarix, a leader in acoustic and AI-based cardiac diagnostics, announced the release of a new study ...

Home April 05, 2023
Home
News | Cardiovascular Clinical Studies

March 29, 2023 — Irregular sleep patterns may play a role in the pathophysiologic development of cardiovascular disease ...

Home March 29, 2023
Home
News | Cardiovascular Clinical Studies

March 27, 2023 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and ...

Home March 27, 2023
Home
News | Cardiovascular Clinical Studies

March 24, 2023 — Vaxxinity, Inc., a Cape Canaveral, FL-based company pioneering the development of a new class of ...

Home March 24, 2023
Home
News | Cardiovascular Clinical Studies

March 22, 2023 — Ancora Heart, Inc., a privately-held Santa Clara, CA-based company developing a completely ...

Home March 22, 2023
Home
News | Cardiovascular Clinical Studies

March 21, 2023 — The first platform to combine real-world cardiology data from millions of people in multiple European ...

Home March 21, 2023
Home
News | Cardiovascular Clinical Studies

March 13, 2023 — BioCardia, Inc., developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2023
Home
News | Cardiovascular Clinical Studies

March 8, 2023 — A unique community-based partnership, the African American Heart Study, will be conducted to measure the ...

Home March 08, 2023
Home
News | Cardiovascular Clinical Studies

March 6, 2023 — A multifaceted intervention to improve prescribing practices increased the likelihood that patients with ...

Home March 06, 2023
Home
Subscribe Now